Literature DB >> 12218710

An informant-based assessment of apathy in Alzheimer disease.

Milton E Strauss1, Susan D Sperry.   

Abstract

OBJECTIVE: To standardize a new rating scale for the assessment of apathy in Alzheimer disease (AD) and report on its reliability, structure, and relation to other clinical features of AD.
BACKGROUND: apathy is a common prominent behavioral syndrome accompanying AD and is associated with excess disability and increased caregiver burden. Current instruments for the assessment of apathy in AD do not explicitly and systematically attempt to differentiate limited activity and engagement due to lack of interest from inability or longstanding, premorbid personality traits. The present assessment, the Dementia Apathy Interview and Rating (DAIR), was developed taking these discriminations into account in question construction and interview format.
METHODS: One hundred participants (50% women) in the University Memory and Aging Center Research Registry with Probable or Possible AD (by NINCDS-ADRDA criteria) were assessed through caregiver interview or direct patient assessment for apathy, depression, and severity of cognitive and functional deficits. Item distribution characteristics, factor analysis, and evaluation of reliability were used to develop the final item set for the DAIR, and correlations with other measures were examined.
RESULTS: A 16-item unidimensional apathy scale with excellent internal consistency (alpha = 0.89) and temporal reliability ( = 0.85 over 2 months) was developed. Individual differences in apathy on the DAIR were unrelated to dysphoria. Apathy was significantly associated with functional and cognitive impairment, while depression was not.
CONCLUSIONS: The DAIR is a reliable informant-based assessment of apathy in persons with AD. Although apathy is assessed with respect to behaviors within the repertoire of patients, this behavioral syndrome remains associated with more severe deficits in cognitive and adaptive functioning. Associations between depression and dementia severity reported in some studies may reflect the confounding of apathy and depression in some assessment instruments.

Entities:  

Mesh:

Year:  2002        PMID: 12218710

Source DB:  PubMed          Journal:  Neuropsychiatry Neuropsychol Behav Neurol        ISSN: 0894-878X


  17 in total

Review 1.  Are the available apathy measures reliable and valid? A review of the psychometric evidence.

Authors:  Diana E Clarke; Jean Y Ko; Emily A Kuhl; Robert van Reekum; Rocio Salvador; Robert S Marin
Journal:  J Psychosom Res       Date:  2010-03-31       Impact factor: 3.006

2.  Italian version of the Starkstein Apathy Scale (SAS-I) and a shortened version (SAS-6) to assess "pure apathy" symptoms: normative study on 392 individuals.

Authors:  Elisabetta Garofalo; Alessandro Iavarone; Sergio Chieffi; Michele Carpinelli Mazzi; Nadia Gamboz; Ferdinando Ivano Ambra; Maria Sannino; Filomena Galeone; Sabrina Esposito; Bruno Ronga; Ciro Rosario Ilardi
Journal:  Neurol Sci       Date:  2020-07-29       Impact factor: 3.307

3.  On the overlap between apathy and depression in dementia.

Authors:  S E Starkstein; L Ingram; M L Garau; R Mizrahi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-08       Impact factor: 10.154

Review 4.  Emotional and Neuropsychiatric Disorders Associated with Alzheimer's Disease.

Authors:  Kenneth M Heilman; Stephen E Nadeau
Journal:  Neurotherapeutics       Date:  2022-01-10       Impact factor: 6.088

Review 5.  Assessing neuropsychiatric symptoms in people with dementia: a systematic review of measures.

Authors:  Laura N Gitlin; Katherine A Marx; Ian H Stanley; Bryan R Hansen; Kimberly S Van Haitsma
Journal:  Int Psychogeriatr       Date:  2014-08-06       Impact factor: 3.878

Review 6.  Epidemiology and management of apathy in patients with Alzheimer's disease.

Authors:  Romina Mizrahi; Sergio E Starkstein
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).

Authors:  Lea T Drye; Roberta W Scherer; Krista L Lanctôt; Paul B Rosenberg; Nathan Herrmann; David Bachman; Jacobo E Mintzer
Journal:  Am J Geriatr Psychiatry       Date:  2013-01-18       Impact factor: 4.105

8.  Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments.

Authors:  Krista L Lanctôt; Roberta W Scherer; Abby Li; Danielle Vieira; Hamadou Coulibaly; Paul B Rosenberg; Nathan Herrmann; Alan J Lerner; Prasad R Padala; Olga Brawman-Mintzer; Chris H van Dyck; Anton P Porsteinsson; Suzanne Craft; Allan Levey; William J Burke; Jacobo E Mintzer
Journal:  Am J Geriatr Psychiatry       Date:  2020-05-27       Impact factor: 4.105

9.  Preserved transcallosal inhibition to transcranial magnetic stimulation in nondemented elderly patients with leukoaraiosis.

Authors:  Giuseppe Lanza; Rita Bella; Salvatore Giuffrida; Mariagiovanna Cantone; Giovanni Pennisi; Concetto Spampinato; Daniela Giordano; Giulia Malaguarnera; Alberto Raggi; Manuela Pennisi
Journal:  Biomed Res Int       Date:  2013-07-25       Impact factor: 3.411

10.  Correlation between Motor Cortex Excitability Changes and Cognitive Impairment in Vascular Depression: Pathophysiological Insights from a Longitudinal TMS Study.

Authors:  Manuela Pennisi; Giuseppe Lanza; Mariagiovanna Cantone; Riccardo Ricceri; Concetto Spampinato; Giovanni Pennisi; Vincenzo Di Lazzaro; Rita Bella
Journal:  Neural Plast       Date:  2016-07-20       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.